悪性胸膜中皮腫患者における細胞減少術および温熱性胸腔内化学療法の周術期炎症の予後効果

To investigate prognostic significance of systemic inflammation-related parameters in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma (MPM).

Data from 55 patients were analyzed retrospectively. Demographic characteristics, survival outcomes and inflammation-related parameters (neutrophil/lymphocyte ratio [NLR], platelet/lymphocyte ratio [PLR], lymphocyte/monocyte ratio [LMR] and pan-immune inflammation value [PIV]) were evaluated.

Overall survival (OS) was 61.26±13.03 (3-79) months in patients with low NLR, whereas, it was 23.18±3.53 (1-147) months in patients with high NLR (p=0.012). No statistically significant differences in OS were detected according to LMR, PLR and PIV. In addition, OS was 24.40±4.91 (3-92) months in men and 52.8±10.92 (1-147) months in women (p=0.031).

In this study, NLR was found to be associated with survival in agreement with the existing literature, thereby distinguishing it from other inflammatory markers as a prognostic factor. In clinical practice, predicting patient prognosis based on pre-treatment NLR may provide a valuable guidance for treatment decision-making.